Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: short interfering RNA-based therapeutics - Silence Therapeutics

Drug Profile

Research programme: short interfering RNA-based therapeutics - Silence Therapeutics

Alternative Names: GalNAc-siRNA - Silence Therapeutics; ICS-283; Research programme: RNAi-based therapeutics -Intradigm/Qiagen; SLN 360

Latest Information Update: 26 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intradigm Corporation
  • Developer Intradigm Corporation; OPKO Health; Silence Therapeutics
  • Class Cardiovascular therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Acromegaly; Alcoholism; Cardiovascular disorders; Metabolic disorders
  • Discontinued Age-related macular degeneration; Cancer; Coronavirus infections; Diabetic retinopathy

Most Recent Events

  • 19 Dec 2018 Silence Therapeutics announces intention to submit IND/CTA for SLN 360 in second half of 2020
  • 19 Dec 2018 Pharmacodynamics data from preclinical studies in Cardiovascular disorders released by Silence Therapeutics
  • 26 Mar 2018 Preclinical trials in Iron overload in United Kingdom (Parenteral) before March 2018 (Silence Therapeutics pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top